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Thiazolidinediones (TZDs)areselective agonistsof theperoxisome proliferator-activatedreceptor(PPAR)gamma, atranscription
factor belonging to the superfamily of nuclear hormone receptors. Although activation of PPARγ by TZDs has been best
characterized by its ability to regulate expression of genes associated with lipid metabolism, PPARγ agonists have other
physiological eﬀects including modulating pro- and anti-inﬂammatory gene expression and inducing apoptosis in several cell
types including glioma cells and cell lines. Immunotherapeutic approaches to reducing brain tumors are focused on means to
reduce the immunosuppressive responses of tumors which dampen the ability of cytotoxic T-lymphocytes to kill tumors. Initial
studies from our lab show that combination of an immunotherapeutic strategy with TZD treatment provides synergistic beneﬁt in
animals with implanted tumors. The potential of this combined approach for treatment of brain tumors is reviewed in this report.
Copyright © 2008 Terry Lichtor et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Thiazolidinediones (TZDs) are synthetic compounds origi-
nally designed as oral antidiabetic drugs [1, 2], but several
reports have indicated other potent biological eﬀects as anti-
inﬂammatory agents [3, 4] and regulators of cell survival
[5]. It has been shown that TZDs induce growth arrest
and cell death in a broad spectrum of tumor cells [6–
10] and hematopoietic cells in vitro and in vivo [11].
At the molecular level, TZDs are speciﬁc ligands of the
peroxisome proliferator-activated receptor gamma (PPAR-
γ),ame mbe ro fthen uc learho rmo ner ec e pt o rfamil y .PP AR -
γ is expressed in many normal tissues, with the highest levels
inadipocytes,consistentwithitsroleinlipidmetabolismand
adipocyte diﬀerentiation [2]. Although the ability of TZDs
to induce PPAR-γ mediated cell diﬀerentiation has been
clearly demonstrated [12–14], the molecular mechanisms
responsible for the growth inhibitory eﬀects of these PPAR-
γ ligands have not been established [15]. TZDs also bind to
a receptor present on the outer mitochondrial membrane
termed “mitoNEET” [16] which may mediate some of
their metabolic eﬀects and also contribute to induction of
apoptosis in tumor cells [17].
Considerable interest has been focused on PPAR-γ
ligands as potential therapeutic agents in the treatment of
gliomas. It has been shown that PPAR-γ ligands can induce
death in both rodent and human glioma cell lines [18–28].
The antineoplastic eﬀects of TZDs have been related to the
ability of these drugs to activate apoptotic pathways [29, 30]
or to interfere with the cell cycle through downregulation
of cyclin D1 [31] and the upregulation of CDK inhibitors
[32, pages (21, 27)]. Interestingly, some studies [24, 27, 33]
have directly compared the eﬀects of TZDs on primary
astrocytes versus transformed cells, with contrasting results.
Two studies [20, 25] showed that ciglitazone, a TZD PPAR-
γ agonist, was toxic to glioma cells as well as to primary
astrocytes, whereas in a third study [27] no toxicity was
induced by ciglitazone in normal astrocytes after eight
days of incubation. The basis for diﬀerential sensitivity of
transformed versus nontransformed cells to TZDs is not
well understood but may involve diﬀerences in metabolic
responses [33].
T h e r ei ss o m ee v i d e n c es u g g e s t i n gt h a tP P A R - γ also
has an immunomodulatory role. In particular, it has been2 PPAR Research
reported that TZDs mediate signiﬁcant inhibition of prolif-
erative responses of both T cell clones and splenocytes [34].
This inhibition occurs in part because the ligands for PPAR-
γ mediate inhibition of interleukin-2 (IL-2) secretion by T
cell clones while not inhibiting IL-2 induced proliferation
of such clones. It has also recently been demonstrated that
PPAR-γ is a negative regulator of dendritic cell maturation
and function [35]. Sustained PPAR-γ activation in murine
dendritic cell reduced maturation-induced expression of
costimulatorymoleculesandIL-12andprofoundlyinhibited
their capacity to prime na¨ ıve CD4+ T cells. Finally, there is
some evidence to suggest that TZDs are potent inhibitors
of glioma cell migration and brain invasion largely by
transcriptional repression of TGF-β [36]. This is particularly
importantbecauseTGF-β isanimmunosuppressivecytokine
that has been shown to have a major role in the malignant
phenotype of gliomas [37]. Furthermore, inhibition of TGF-
β signaling restores immune surveillance and is associated
with improved survival in a glioma model [37].
We previously reported the immunotherapeutic proper-
ties of interleukin-2 secreting syngeneic/allogeneic cells in
the treatment of brain tumors in mice [38]. Mice with an
intracerebral (i.c.) glioma treated solely by intratumor injec-
tions with allogeneic cells genetically modiﬁed to secrete IL-
2 survived signiﬁcantly longer than mice in various control
groups. The antitumor response was mediated predomi-
nantly by CD8+ T cells and NK/LAK cells [39]. Intratumoral
injections of the cytokine-secreting cells resulted in the
killing of only the neoplastic cells; nonneoplastic cells were
unaﬀected. Of special interest, mice injected intracerebrally
with the cytokine-secreting allogeneic cells alone exhibited
no neurologic deﬁcit and there was no adverse eﬀects on
survival. The injection of IL-2 secreting allogeneic cells into
themicroenvironmentofani.c.tumorinducedanantitumor
immune response capable of prolonging survival.
In another study, the possible beneﬁts of combining
administrationofthechemotherapeuticagentpaclitaxelwith
immunotherapyinthetreatmentofC3H/Hemicebearingan
established highly aggressive intracerebral breast cancer was
explored [40]. Paclitaxel is a widely-used chemotherapeutic
agent which is known to induce apoptosis, although the
mechanism of action is poorly understood [41]. The mice
were treated by injection into the tumor bed with the DNA-
based vaccine, with paclitaxel administered intraperitoneally
or by paclitaxel followed by immunization with the DNA-
based vaccine. The results indicated that the survival of mice
withanestablishedintracerebralbreastcancerwasprolonged
by treatment with either paclitaxel or the DNA-transfected
ﬁbroblasts (P < .025), but survival of mice receiving the
combinedtherapydidnotexceedthatoftumor-bearingmice
receiving either form of treatment alone. The suppression
of the peripheral white blood cell count attributed to pacli-
taxel, although relatively brief, makes paclitaxel along with
most chemotherapeutic agents somewhat antagonistic when
administered with immunotherapeutic treatment strategies.
Nevertheless, the combination of systemic chemotherapy
along with immunotherapy has been used to treat patients
with advanced-stage carcinoma [42]. It has been pro-
posed that dying tumor cells, particularly those killed by
chemotherapy, engage with antitumor immune responses
[43].
Since the tumor cell population is known to be het-
erogeneous and includes cells that are resistant to cellular
immune mechanisms, it is likely that there is a subpop-
ulation of tumor cells that are resistant to host immune
mechanisms. In order to control tumor growth, a combi-
nation of therapeutic strategies will be required. Although
thiazolidinediones reduce the antigen presenting capacity
of dendritic cells along with reducing T cell proliferation
and cytokine secretion, TZDs do not suppress the immune
system and bone marrow in the same fashion as typical
chemotherapeutic agents such that these agents should
not compete with immune therapeutic strategies in the
treatment of various tumors. In addition, their metabolic
eﬀectswouldbeexpectedtooccurindependentofcellorigin.
To test this, we carried out studies in C57Bl/6 mice
with an established glioma [44]. The results of that study
showed that oral pioglitazone was not eﬀective in prolonging
survival in mice bearing a highly malignant glioma (Gl261)
grown intracerebrally in syngeneic C57Bl/6 mice. Intracere-
bral injection of pioglitazone was eﬀective in prolonging
survival in mice with an intracerebral glioma. Furthermore,
intracerebral injection of ﬁbroblasts genetically engineered
to secrete IL-2 into an established intracerebral glioma
was eﬀective both in prolonging survival and stimulating a
systemic antitumor immune response as measured in the
spleen cells using an IFN-γ ELISPOT assay. In previous
studies, it was conﬁrmed that the antitumor immune
responses in the tumor bearing mice were mediated pre-
dominantly by CD8+ and NK/LAK cells [39]. However,
there was a synergistic response in prolonging survival
of the animals with an established intracerebral glioma
treated with both IL-2 secreting ﬁbroblasts and piogli-
tazone. It should be noted nevertheless that splenic T
cells isolated from mice treated with both IL-2 secreting
cells and pioglitazone showed no increase in response
as compared with the spleen cells isolated from animals
t r e a t e dw i t hI L - 2s e c r e t i n gﬁ b r o b l a s t sa l o n ea sm e a s u r e d
by the ELISPOT IFN-γ assay. These results suggest that
the tendency of pioglitatzone to increase the mean survival
time in mice bearing a glioma is not due to an increase
in systemically driven T cell immunity against the Gl261
cells.
The above results suggest that treatment with TZDs can
syngergize with immunotherapeutic approaches to increase
glioma cell death. While the mechanisms involved remain
to be elucidated, it is likely to be a combination of events
including a reduction in the immunosuppressive responses
of the tumor cells leading to an increase in cytotoxic T
c e l ln u m b e r so ra c t i v i t ya sw e l la sad e c r e a s ei nt u m o rc e l l
mitochondrial function making the cells more susceptible to
induction of apoptosis by cytokines.
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